NEWS TODAY
Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD
Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE'
Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER' trial in DLB
PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will deliver an oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference, which is taking place October 29 - November 1, 2024, in Madrid, Spain.
"Dr. Woodward will present results from pre-specified analyses that give a robust picture of the positive results from the Phase 2 ‘SHINE' trial of CT1812 in mild-to-moderate Alzheimer's disease," explained Anthony O. Caggiano, MD, PhD, Cognition's CMO and head of R&D. "We believe the consistent efficacy signals observed in patients treated with CT1812 for six months, coupled with a favorable tolerability profile, support our plans to advance CT1812 for the treatment of people with mild-to-moderate Alzheimer's disease."
Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER' trial in DLB
PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will deliver an oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference, which is taking place October 29 - November 1, 2024, in Madrid, Spain.
"Dr. Woodward will present results from pre-specified analyses that give a robust picture of the positive results from the Phase 2 ‘SHINE' trial of CT1812 in mild-to-moderate Alzheimer's disease," explained Anthony O. Caggiano, MD, PhD, Cognition's CMO and head of R&D. "We believe the consistent efficacy signals observed in patients treated with CT1812 for six months, coupled with a favorable tolerability profile, support our plans to advance CT1812 for the treatment of people with mild-to-moderate Alzheimer's disease."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2537Followers
107Following
27KVisitors
Follow